News Sentiment

CAI sentiment intelligence

Caris Life Sciences, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 78 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 16.49 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

81/100 classification confidence.

Company focus 70

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend inactive

-2.9% over one week, -10.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Biomarker Collaboration and Licensing Deals Report 2016-2026 - Featuring Quanterix, Caris Life Sciences, Alnylam Pharmaceuticals, Guardant Health, Eurofins Scientific and More

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 81/100 classification
One-week reaction -2.9% Price reacting lower
Trend fit Trend inactive -10.7% over four weeks
Fair value -33.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 28
Neutral 46
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 70
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Stock Titan 12
simplywall.st 7
PR Newswire 5
MarketBeat 3
Morningstar 3
The Globe and Mail 2
TIKR.com 2

Event Lens

What the news is about

Classified themes
Market update 44
Earnings 22
Analyst action 5
Capital return 3
Balance sheet 2
Regulatory and legal 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 78
Stock Titan Direct company coverage

[Form 4] Caris Life Sciences, Inc. Insider Trading Activity

Caris Life Sciences director Jon Halbert reported an open-market purchase of 68,000 shares of Common Stock on May 15, 2026, at a weighted average price of $14.56 per share. This transaction was conducted through LAH Investments, Ltd., increasing its indirect holdings to 704,598 s

Tone
Positive 70/100
Event
Market update
Published
13 Jul 2026 15:39
Source
Stock Titan
MarketBeat Direct company coverage

Insider Buying: Caris Life Sciences (NASDAQ:CAI) Director Acquires $990,080.00 in Stock

Caris Life Sciences (NASDAQ:CAI) Director Jon Halbert purchased 68,000 shares of the company's stock for $990,080 on May 15th, increasing his total ownership to 704,598 shares. This insider buying comes as the company also announced a $100 million share repurchase program, sugges

Tone
Positive 67/100
Event
Capital return
Published
13 Jul 2026 15:39
Source
MarketBeat
Investing.com Canada Direct company coverage

Form 4 Caris Life Sciences Inc For: 13 July By Investing.com

This article reports on a Form 4 filing for Caris Life Sciences Inc., dated July 13. Form 4s disclose transactions made by company insiders, and are routinely published by Investing.com. The information provided is brief, stating only the company name and filing date.

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 07:30
Source
Investing.com Canada
MarketBeat Direct company coverage

Caris Life Sciences, Inc. (NASDAQ:CAI) Receives Consensus Recommendation of "Hold" from Brokerages

Caris Life Sciences, Inc. (NASDAQ:CAI) has received a consensus "Hold" rating from eleven brokerages, with an average 12-month price target of $26.11. Insider activity shows Director Jeff L. Vacirca increasing his stake by 166.75%, and the company's board has authorized a $100 mi

Tone
Positive 58/100
Event
Analyst action
Published
11 Jul 2026 02:11
Source
MarketBeat
Morningstar Direct company coverage

Caris Life Sciences Announces Dual Listing on NYSE Texas

Caris Life Sciences (NASDAQ: CAI) announced a dual listing of its common stock on NYSE Texas, effective June 17, 2026. This move expands its presence in public markets while retaining its primary listing on NASDAQ. The dual listing is intended to provide additional exposure to in

Tone
Positive 71/100
Event
Market update
Published
17 Jun 2026 05:10
Source
Morningstar
Stock Titan Direct company coverage

AI precision-medicine company Caris adds NYSE Texas listing

Caris Life Sciences, a patient-centric AI TechBio and precision medicine company, announced a dual listing of its common stock on NYSE Texas, effective June 17, 2026. Shares will continue to trade on NASDAQ under the CAI ticker while also listing on NYSE Texas, aiming for increas

Tone
Positive 75/100
Event
Market update
Published
16 Jun 2026 12:39
Source
Stock Titan